Hormonal
Roux-en-Y gastric bypass (RYGBP) accelerates exogenous glucose appearance and enhances postprandial GLP-1 and PYY secretion compared to gastric banding (GB) and controls, leading to earlier and higher insulin peaks and faster glucose clearance.
For individuals undergoing Roux-en-Y gastric bypass, the procedure triggers a rapid release of gut hormones (GLP-1, PYY) and faster glucose absorption, which leads to a stronger and earlier insulin response. This hormonal shift helps clear glucose from the blood faster than in non-surgical individuals or those with gastric banding, contributing to improved glucose control even before significant weight loss occurs.
Patients who had undergone RYGBP showed a more rapid appearance of exogenous glucose in the systemic circulation and a shorter duration of postprandial hyperglycemia than patients who had undergone GB and C. The response in RYGBP patients was characterized by early and accentuated insulin response, enhanced postprandial levels of glucagon-like peptide-1 (GLP-1) and polypeptide YY (PYY), and greater postprandial suppression of ghrelin.
Why this rating
Controlled cross-sectional study with rigorous tracer methods, but small sample size (n=8 per group) and specific population (women, non-diabetic).
Source
Effects of Gastric Bypass and Gastric Banding on Glucose Kinetics and Gut Hormone Release
Frédérique Rodieux et al. · Obesity · 2008
DOI 10.1038/oby.2007.83
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →